Poseida Therapeutics, Inc.
PSTXDelisted Jan 8, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001661460
Poseida Therapeutics, Inc. was delisted on Jan 8, 2025; its insiders filed their last Form 4 on Jan 10, 2025; 116 institutions reported holding it in 13F filings for Q4 2024, worth $519.2M in total; no superinvestor held it.
Q4 2022 vs. Q3 2022
How the institutions holding Poseida Therapeutics, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 68 | 89 | +21 |
| Shares | 40.1M | 43.0M | +2.95M (+7.4%) |
| Value | $141.8M | $227.6M | +$85.8M (+60.6%) |
New holders (30)
Institutions that held Poseida Therapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
Sold out (9)
Institutions that held Poseida Therapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Perceptive Advisors LLC | 750,000 | $2.65M |
| Sphera Funds Management Ltd. | 300,000 | $1.06M |
| Ergoteles LLC | 93,842 | $331.0K |
| Barr E S & Co | 76,398 | $270.0K |
| Cantor Fitzgerald, L. P. | 45,205 | $160.0K |
| Parkside Financial Bank & Trust | 3,200 | $11.0K |
| Rockefeller Capital Management L.P. | 1,250 | $4.00K |
| BNP Paribas Arbitrage, SA | 452 | $1.60K |
| Dark Forest Capital Management LP | 20 | $0 |